What is she best known for?
The fields of study she is best known for:
Lois M. Mulligan focuses on Cancer research, RET proto-oncogene, Germline mutation, Multiple endocrine neoplasia and Genetics.
Her Cancer research research is multidisciplinary, relying on both Missense mutation, Endocrine cancer, Carcinogenesis, Tumor suppressor gene and Point mutation.
The RET proto-oncogene study combines topics in areas such as Receptor tyrosine kinase, Multiple endocrine neoplasia type 2, Mutation and Multiple endocrine neoplasia type 2b.
Her Multiple endocrine neoplasia type 2 research is multidisciplinary, incorporating perspectives in Internal medicine, Proto-Oncogene Proteins c-ret and Endocrinology.
Her study in Germline mutation is interdisciplinary in nature, drawing from both Pheochromocytoma, Thyroid carcinoma and Germline.
Her biological study spans a wide range of topics, including Mutation and Medullary carcinoma.
Her most cited work include:
- Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (1617 citations)
- The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. (977 citations)
- Mutations of the RET proto-oncogene in Hirschsprung's disease (632 citations)
What are the main themes of her work throughout her whole career to date?
Lois M. Mulligan mostly deals with Genetics, Cancer research, RET proto-oncogene, Multiple endocrine neoplasia type 2 and Internal medicine.
The study incorporates disciplines such as Germline mutation, Carcinogenesis, Receptor tyrosine kinase, Multiple endocrine neoplasia and Proto-Oncogene Proteins c-ret in addition to Cancer research.
Her Germline mutation study integrates concerns from other disciplines, such as Medullary carcinoma, Thyroid carcinoma, Germline and Pathology.
Her RET proto-oncogene research incorporates themes from Neural crest, Mutation, Point mutation and Multiple endocrine neoplasia type 2b.
Her Multiple endocrine neoplasia type 2 research integrates issues from Pheochromocytoma and Oncogene RET.
Her studies deal with areas such as Endocrinology, Kinase and Oncology as well as Internal medicine.
She most often published in these fields:
- Genetics (52.53%)
- Cancer research (43.04%)
- RET proto-oncogene (29.75%)
What were the highlights of her more recent work (between 2012-2020)?
- Cell biology (13.92%)
- Cancer research (43.04%)
- Receptor tyrosine kinase (15.82%)
In recent papers she was focusing on the following fields of study:
Cell biology, Cancer research, Receptor tyrosine kinase, Glial cell line-derived neurotrophic factor and Receptor are her primary areas of study.
Her work deals with themes such as Endocrinology, Internal medicine and Internalization, which intersect with Cell biology.
Her Endocrinology research incorporates elements of Mutation, Germline mutation, Frameshift mutation and Germline.
Her research on Internal medicine frequently connects to adjacent areas such as Multiple endocrine neoplasia type 2.
Her Cancer research research is multidisciplinary, incorporating elements of Neurotrophic factors, Lung cancer and Cell signaling.
Her Receptor study combines topics in areas such as Function, Kinase, Kinase activity, RET proto-oncogene and Protein kinase domain.
Between 2012 and 2020, her most popular works were:
- RET revisited: expanding the oncogenic portfolio (291 citations)
- A comprehensive review on MEN2B (31 citations)
- GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential (30 citations)
In her most recent research, the most cited papers focused on:
Her scientific interests lie mostly in Cancer research, Cell biology, Receptor tyrosine kinase, Cell signaling and Cell.
Her Cancer research research is multidisciplinary, incorporating elements of Mutation, Germline mutation, Cancer and Endocrinology.
Her Cell signaling study also includes
- Endocrine cancer which connect with Kinase,
- Cell culture which intersects with area such as Tumor microenvironment.
The study incorporates disciplines such as Mesenchymal stem cell, Gene knockdown and Cell growth in addition to Cell.
Lois M. Mulligan has included themes like Missense mutation, Gene, RET proto-oncogene and Kinase activity in her Receptor study.
Her Medullary thyroid cancer research is multidisciplinary, incorporating perspectives in Multiple endocrine neoplasia type 2, Germline, Proto-Oncogene Proteins c-ret and Frameshift mutation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
